Aurinia Pharmaceuticals Inc

20.79-0.7100-3.30%Vol 6.28M1Y Perf 42.08%
Sep 15th, 2021 16:00 DELAYED
BID20.68 ASK20.89
Open21.17 Previous Close21.50
Pre-Market20.79 After-Market-
 - -%  - -
Target Price
31.00 
Analyst Rating
Strong Buy 1.16
Potential %
49.11 
Finscreener Ranking
★★★★+     57.64
Insiders Trans % 3/6/12 mo.
-100/-7/10 
Value Ranking
★★★★     54.88
Insiders Value % 3/6/12 mo.
-100/-80/-76 
Growth Ranking
★★★★+     63.63
Insiders Shares Cnt. % 3/6/12 mo.
-100/-70/-69 
Income Ranking
 —    -
Price Range Ratio 52W %
91.19 
Earnings Rating
Strong Sell
Market Cap2.67B 
Earnings Date
9th Nov 2021
Alpha0.06 Standard Deviation0.29
Beta0.48 

Today's Price Range

20.2621.40

52W Range

9.7221.86

5 Year PE Ratio Range

-8.30-8.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
7.44%
1 Month
43.78%
3 Months
64.61%
6 Months
50.33%
1 Year
42.08%
3 Years
268.62%
5 Years
909.22%
10 Years
-

TickerPriceChg.Chg.%
AUPH20.79-0.7100-3.30
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
11.00
11.90
0.02
0.03
-1 442.40
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
58.30
-245.20
-241.50
-14 421.50
-
RevenueValueIndustryS&P 500US Markets
57.59M
0.45
511.27
171.43
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.35-0.37-5.71
Q01 2021-0.35-0.40-14.29
Q04 2020-0.31-0.0583.87
Q03 2020-0.22-0.28-27.27
Q02 2020-0.23-0.26-13.04
Q01 2020-0.20-0.1525.00
Q04 2019-0.21-0.29-38.10
Q03 2019-0.19-0.21-10.53
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.31-24.00Negative
12/2021 QR-0.23-53.33Negative
12/2021 FY-1.34-12.61Negative
12/2022 FY-0.43-38.71Negative
Next Report Date9th Nov 2021
Estimated EPS Next Report-0.31
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume6.28M
Shares Outstanding128.40M
Shares Float127.87M
Trades Count31.08K
Dollar Volume91.48M
Avg. Volume4.13M
Avg. Weekly Volume5.10M
Avg. Monthly Volume4.11M
Avg. Quarterly Volume3.92M

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 20.79 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 6.31M shares and market capitalization of 2.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.

The one-year performance of Aurinia Pharmaceuticals Inc stock is 42.08%, while year-to-date (YTD) performance is 50.33%. AUPH stock has a five-year performance of 909.22%. Its 52-week range is between 9.72 and 21.86, which gives AUPH stock a 52-week price range ratio of 91.19%

Aurinia Pharmaceuticals Inc currently has a PE ratio of -11.10, a price-to-book (PB) ratio of 5.11, a price-to-sale (PS) ratio of 46.66, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -42.30%, a ROC of -43.37% and a ROE of -50.50%. The company’s profit margin is -%, its EBITDA margin is -241.50%, and its revenue ttm is $57.59 Million , which makes it $0.45 revenue per share.

Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.31 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is 09th Nov 2021.

The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Strong Buy (1.16), with a target price of $31, which is +49.11% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aurinia Pharmaceuticals Inc has a Buy technical analysis rating based on Technical Indicators (ADX : 13.77, ATR14 : 1.26, CCI20 : 125.36, Chaikin Money Flow : 0.32, MACD : 1.79, Money Flow Index : 79.31, ROC : 17.46, RSI : 71.10, STOCH (14,3) : 83.71, STOCH RSI : 0.41, UO : 69.29, Williams %R : -16.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: George M. Milne (Buy at a value of $65 000), Jill D. Leversage (Buy at a value of $53 037), Joseph M. Miller (Buy at a value of $9 740), Matthew Donley (Buy at a value of $99 739), Michael Hayden (Option Excercise at a value of $550 100), Michael R. Martin (Option Excercise at a value of $60 400), Michael R. Martin (Sold 45 000 shares of value $754 625 ), Neil Solomons (Option Excercise at a value of $120 800), Neil Solomons (Sold 90 000 shares of value $1 340 200 ), R. Hector Mackay-Dunn (Buy at a value of $50 529), Robert Huizinga (Option Excercise at a value of $241 600), Robert Huizinga (Sold 5 000 shares of value $91 500 ), Stephen P. Robertson (Buy at a value of $14 526)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (87.50 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (12.50 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.16
Strong Buy
1.16
Strong Buy
1.19

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

CEO: Peter S. Greenleaf

Telephone: +1 250 708-4272

Address: 4464 Markham Street, Victoria V8Z 7X8, BC, CA

Number of employees: 294

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

61%39%

Bearish Bullish

66%34%

News

Stocktwits